Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BristolMyers

What's Behind the Insider Buying on This High-Yield Stock?

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

Bristol-Myers Squibb Stock: Analyst Estimates & Ratings

Bristol-Myers Squibb Stock: Analyst Estimates & Ratings

Bristol-Myers Squibb has underperformed the market over the past year, and Wall Street analysts remain cautious about the stock prospects.

Bristol Myers Surpasses Expectations with Q4 Results

Bristol Myers Surpasses Expectations with Q4 Results

Bristol Myers has reported better-than-expected 4th-quarter results, indicating positive performance for the company.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

2 High-Yield Value Stocks to Buy Now

Here's a look at two dividend value stocks with high yields that Wall Street recommends buying.

3 Buy-Rated S&P 500 Stocks to Scoop Up Near 52-Week Lows

Beaten-down blue-chip stocks, such as United Parcel Services, look poised to deliver double-digit returns to shareholders in the next year.

Bristol Myers Stock Surges After FDA Approves New Plaque Psoriasis Treatment; Amgen Slides

“We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.

Bristol Myers Stock Slumps After Mixed Data From Stroke Drug Trial

"Secondary strokes continue to be a serious health risk for stroke patients and we believe these data demonstrated the potential of milvexian to address a key unmet need in this population," Bristol Myers said.

inkl

Read news from The Economist, FT, and more,
with one subscription

Bristol Myers

"Secondary strokes continue to be a serious health risk for stroke patients and we believe these data demonstrated the potential of milvexian to address a key unmet need in this population," Bristol Myers said.

Bristol Myers Q2 Earnings Top Street Forecasts On Solid Eliquis and Opdivo Sales

Bristol Myers Q2 Earnings Top Street Forecasts On Solid Eliquis and Opdivo Sales

Solid cancer and blood clot treatment sales, as well as a smaller-than-forecast decline for Revlimid, helped deliver a top and bottom line beat for drugmaker Bristol Myers.

Bristol Myers to Buy Turning Point Therapeutics in $4.1 Billion Oncology Deal

Bristol Myers to Buy Turning Point Therapeutics in $4.1 Billion Oncology Deal

“With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile," said Bristol Myers CEO Giovanni Caforio.

1

Organisations

BristolMyers Squibb Company

United Parcel Service

Bristol Myers Squibb

Waste Management

BristolMyers Squibb

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

243,758 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play